FIELD: biotechnologies.
SUBSTANCE: invention represents a cleaned mutant protein of O-streptolysin with SEQ ID NO:1 sequence, where amino acids in positions P427 and W535 are replaced with another amino acid, or with SEQ ID NO:25 sequence. With that, hemolytic activity of SLO mutant protein is reduced at least by 50% in comparison to SLO of a wild type. The invention also refers to vaccine compositions for prophylaxis of an infection caused by S. pyogenes and containing the above streptolysin protein.
EFFECT: invention allows obtaining mutant shapes of O-streptolysin, which are non-toxic, but which still maintain the ability of inducing protection against S pyogenes and can be used in vaccine compositions for induction of protection against S pyogenes.
15 cl, 26 dwg, 21 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MUTANT ANTIGENS GAS57 AND GAS57 ANTIBODIES | 2008 |
|
RU2471497C2 |
| OUTER MEMBRANE VESICLES | 2013 |
|
RU2662970C2 |
| MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS BASED THEREON AND THEIR APPLICATION | 2012 |
|
RU2632651C2 |
| CONJUGATES OF GHRELIN CARRIER | 2003 |
|
RU2325202C2 |
| MUTANT HEAT-LABILE ENTEROTOXIN E. coli | 2007 |
|
RU2441879C2 |
| IMMUNOGENE COMPOSITION ON BASIS OF ANTIGEN Chlamydia trachomatis (VERSIONS) AND ITS USE | 2004 |
|
RU2352356C2 |
| ANTIGEN MATRIX FOR TREATMENT OF BONE DISEASE | 2002 |
|
RU2322258C2 |
| STABILISED FMDV CAPSIDS | 2014 |
|
RU2663004C2 |
| IMMUNOPROPHYLACTIC CANCER VACCINE | 2004 |
|
RU2556128C2 |
| HAPTEN-CARRIER CONJUGATES AND APPLICATION | 2003 |
|
RU2326693C2 |
